A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

November 19, 2012

Single-Tablet Complera Combo Regimen Proves Comparable to Atripla

Complera proved to be “non-inferior” to, and in some cases more effective than, Atripla in a Phase IIIb study comparing the two single-pill, triple combination antiretroviral therapy regimens among treatment-naive people with HIV, the Business Wire reports. Gilead Sciences, which manufactures Complera (emtricitabine/rilpivirine/tenofovir) announced the findings from its STaR (Single Tablet Regimen) study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow.

The study compared the rates of undetectable viral loads after 48 weeks of therapy between 394 participants taking Complera, which was approved in the United States in 2011, and another 392 taking Atripla (efavirenz/emtricitabine/tenofovir), the standard of care for treatment-naive people with HIV since its approval in 2006. Overall, 86 percent of those taking Complera and 82 percent of those on Atripla reached an undetectable viral load. Complera maintained a statistically significant advantage among those with a baseline viral load at or below 100,000, with 89 percent reaching undetectable compared with Atripla’s 82 percent. Meanwhile, 80 percent of Complera patients and 82 percent of Atripla patients with baseline viral loads above 100,000 achieved viral suppression.

To read the Business Wire report, click here.

To read Gilead’s release, click here.

Search: HIV, Complera, non-inferior, Atripla, comparble, Phase IIIb, emtricitabine, rilpivirine, tenofovir, STaR, Single Tablet Regimen, 11th International Congress on Drug Therapy in HIV Infection in Glasgow, undetectable viral load, viral suppression.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dversescott
    Baltimore
    Maryland


    Newhopenate
    New Hope
    Pennsylvania


    Fred9774
    Brooklyn
    New York


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.